UNIVERSAL TECHNICAL INSTITUT (UTI) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:UTI - US9139151040 - Common Stock
27.815 USD
+1.23 (+4.61%)
We assign a fundamental rating of 5 out of 10 to UTI. UTI was compared to 76 industry peers in the Diversified Consumer Services industry. While UTI has a great profitability rating, there are some minor concerns on its financial health. While showing a medium growth rate, UTI is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year UTI was profitable.
- In the past year UTI had a positive cash flow from operations.
- Each year in the past 5 years UTI has been profitable.
- UTI had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- UTI's Return On Assets of 7.63% is fine compared to the rest of the industry. UTI outperforms 72.37% of its industry peers.
- The Return On Equity of UTI (19.21%) is better than 82.89% of its industry peers.
- The Return On Invested Capital of UTI (10.46%) is better than 82.89% of its industry peers.
- UTI had an Average Return On Invested Capital over the past 3 years of 7.27%. This is below the industry average of 10.30%.
- The 3 year average ROIC (7.27%) for UTI is below the current ROIC(10.46%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.63% | ||
| ROE | 19.21% | ||
| ROIC | 10.46% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
1.3 Margins
- Looking at the Profit Margin, with a value of 7.54%, UTI is in the better half of the industry, outperforming 67.11% of the companies in the same industry.
- UTI's Profit Margin has improved in the last couple of years.
- UTI's Operating Margin of 9.99% is fine compared to the rest of the industry. UTI outperforms 65.79% of its industry peers.
- UTI's Operating Margin has improved in the last couple of years.
- Looking at the Gross Margin, with a value of 49.68%, UTI is in line with its industry, outperforming 55.26% of the companies in the same industry.
- UTI's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.99% | ||
| PM (TTM) | 7.54% | ||
| GM | 49.68% |
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), UTI is creating some value.
- The number of shares outstanding for UTI has been increased compared to 1 year ago.
- The number of shares outstanding for UTI has been increased compared to 5 years ago.
- UTI has a better debt/assets ratio than last year.
2.2 Solvency
- UTI has an Altman-Z score of 3.29. This indicates that UTI is financially healthy and has little risk of bankruptcy at the moment.
- UTI has a Altman-Z score of 3.29. This is in the better half of the industry: UTI outperforms 78.95% of its industry peers.
- The Debt to FCF ratio of UTI is 1.57, which is an excellent value as it means it would take UTI, only 1.57 years of fcf income to pay off all of its debts.
- UTI's Debt to FCF ratio of 1.57 is amongst the best of the industry. UTI outperforms 84.21% of its industry peers.
- A Debt/Equity ratio of 0.26 indicates that UTI is not too dependend on debt financing.
- UTI has a Debt to Equity ratio (0.26) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.57 | ||
| Altman-Z | 3.29 |
ROIC/WACC1.23
WACC8.5%
2.3 Liquidity
- A Current Ratio of 1.07 indicates that UTI should not have too much problems paying its short term obligations.
- UTI has a Current ratio (1.07) which is comparable to the rest of the industry.
- UTI has a Quick Ratio of 1.07. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
- UTI has a Quick ratio of 1.07. This is comparable to the rest of the industry: UTI outperforms 50.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.07 | ||
| Quick Ratio | 1.07 |
3. Growth
3.1 Past
- UTI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.05%, which is quite impressive.
- The Earnings Per Share has been growing by 65.96% on average over the past years. This is a very strong growth
- UTI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.05%.
- UTI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.67% yearly.
EPS 1Y (TTM)54.05%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%0%
Revenue 1Y (TTM)14.05%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%13.28%
3.2 Future
- Based on estimates for the next years, UTI will show a very negative growth in Earnings Per Share. The EPS will decrease by -11.51% on average per year.
- Based on estimates for the next years, UTI will show a quite strong growth in Revenue. The Revenue will grow by 8.99% on average per year.
EPS Next Y-31.68%
EPS Next 2Y-11.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year9.23%
Revenue Next 2Y8.99%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 24.40, UTI is valued on the expensive side.
- UTI's Price/Earnings is on the same level as the industry average.
- Compared to an average S&P500 Price/Earnings ratio of 27.33, UTI is valued at the same level.
- The Price/Forward Earnings ratio is 35.71, which means the current valuation is very expensive for UTI.
- UTI's Price/Forward Earnings ratio is in line with the industry average.
- UTI's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 24.12.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.4 | ||
| Fwd PE | 35.71 |
4.2 Price Multiples
- UTI's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. UTI is cheaper than 63.16% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, UTI is valued a bit cheaper than the industry average as 64.47% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.35 | ||
| EV/EBITDA | 11.37 |
4.3 Compensation for Growth
- The decent profitability rating of UTI may justify a higher PE ratio.
- UTI's earnings are expected to decrease with -11.51% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.37
EPS Next 2Y-11.51%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- UTI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:UTI (1/15/2026, 3:13:05 PM)
27.815
+1.23 (+4.61%)
Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)11-19 2025-11-19/amc
Earnings (Next)02-03 2026-02-03
Inst Owners97.52%
Inst Owner Change3.35%
Ins Owners2.78%
Ins Owner Change5.07%
Market Cap1.51B
Revenue(TTM)835.62M
Net Income(TTM)63.02M
Analysts81.82
Price Target38.18 (37.26%)
Short Float %4.93%
Short Ratio3.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)49.09%
Min EPS beat(2)28.91%
Max EPS beat(2)69.26%
EPS beat(4)4
Avg EPS beat(4)73.64%
Min EPS beat(4)28.91%
Max EPS beat(4)123.12%
EPS beat(8)7
Avg EPS beat(8)75.72%
EPS beat(12)10
Avg EPS beat(12)77.26%
EPS beat(16)14
Avg EPS beat(16)214.91%
Revenue beat(2)2
Avg Revenue beat(2)0.81%
Min Revenue beat(2)0.47%
Max Revenue beat(2)1.15%
Revenue beat(4)4
Avg Revenue beat(4)2.24%
Min Revenue beat(4)0.47%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.25%
Revenue beat(12)12
Avg Revenue beat(12)3.17%
Revenue beat(16)15
Avg Revenue beat(16)3.41%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)1.61%
EPS NQ rev (3m)-43.81%
EPS NY rev (1m)-2.53%
EPS NY rev (3m)-21.31%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)-0.64%
Revenue NY rev (1m)0.16%
Revenue NY rev (3m)0.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.4 | ||
| Fwd PE | 35.71 | ||
| P/S | 1.81 | ||
| P/FCF | 27.35 | ||
| P/OCF | 15.56 | ||
| P/B | 4.61 | ||
| P/tB | 5.36 | ||
| EV/EBITDA | 11.37 |
EPS(TTM)1.14
EY4.1%
EPS(NY)0.78
Fwd EY2.8%
FCF(TTM)1.02
FCFY3.66%
OCF(TTM)1.79
OCFY6.43%
SpS15.35
BVpS6.03
TBVpS5.19
PEG (NY)N/A
PEG (5Y)0.37
Graham Number12.43
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.63% | ||
| ROE | 19.21% | ||
| ROCE | 13.99% | ||
| ROIC | 10.46% | ||
| ROICexc | 14.6% | ||
| ROICexgc | 16.35% | ||
| OM | 9.99% | ||
| PM (TTM) | 7.54% | ||
| GM | 49.68% | ||
| FCFM | 6.62% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
ROICexc(3y)10.21%
ROICexc(5y)8.25%
ROICexgc(3y)11.54%
ROICexgc(5y)9.21%
ROCE(3y)9.72%
ROCE(5y)7.88%
ROICexgc growth 3Y34.26%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.76%
ROICexc growth 5YN/A
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
F-Score6
Asset Turnover1.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.57 | ||
| Debt/EBITDA | 0.72 | ||
| Cap/Depr | 127.37% | ||
| Cap/Sales | 5.02% | ||
| Interest Coverage | 14.13 | ||
| Cash Conversion | 83.6% | ||
| Profit Quality | 87.84% | ||
| Current Ratio | 1.07 | ||
| Quick Ratio | 1.07 | ||
| Altman-Z | 3.29 |
F-Score6
WACC8.5%
ROIC/WACC1.23
Cap/Depr(3y)145.01%
Cap/Depr(5y)268.95%
Cap/Sales(3y)5.89%
Cap/Sales(5y)11.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.05%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%0%
EPS Next Y-31.68%
EPS Next 2Y-11.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)14.05%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%13.28%
Revenue Next Year9.23%
Revenue Next 2Y8.99%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y36.41%
EBIT growth 3Y47.33%
EBIT growth 5YN/A
EBIT Next Year46.16%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.14%
FCF growth 3YN/A
FCF growth 5Y99.08%
OCF growth 1Y13.31%
OCF growth 3Y28.35%
OCF growth 5Y54.57%
UNIVERSAL TECHNICAL INSTITUT / UTI FAQ
What is the fundamental rating for UTI stock?
ChartMill assigns a fundamental rating of 5 / 10 to UTI.
What is the valuation status for UTI stock?
ChartMill assigns a valuation rating of 3 / 10 to UNIVERSAL TECHNICAL INSTITUT (UTI). This can be considered as Overvalued.
Can you provide the profitability details for UNIVERSAL TECHNICAL INSTITUT?
UNIVERSAL TECHNICAL INSTITUT (UTI) has a profitability rating of 7 / 10.
Can you provide the financial health for UTI stock?
The financial health rating of UNIVERSAL TECHNICAL INSTITUT (UTI) is 6 / 10.
What is the earnings growth outlook for UNIVERSAL TECHNICAL INSTITUT?
The Earnings per Share (EPS) of UNIVERSAL TECHNICAL INSTITUT (UTI) is expected to decline by -31.68% in the next year.